Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called AIN457 (also known as secukinumab) for people with a type of eye inflammation affecting the middle or back of the eye (uveitis). A total of 125 people took part in the core part of the study, split across four groups: one group received AIN457 300 mg every two weeks (29 people), one received AIN457 300 mg every four weeks (31 people), one received AIN457 150 mg every four weeks (31 people), and one received a placebo — a dummy treatment with no active ingredient (34 people). A smaller group of 70 people then continued into an extension phase of the study. The trial was mainly measuring how long it took before participants experienced a return of their eye inflammation after the study began. The reported data shows that for the main (primary) outcome — the estimated time until eye inflammation returned — no numerical values were reported for any of the four groups; this figure was listed as "NA" (not available) in the submitted data. For the secondary outcomes, the data shows that the number of participants whose inflammation returned during the combined core and extension studies varied across groups: 8 out of 29 in the highest-dose fortnightly group, 11 out of 31 in the monthly 300 mg group, 10 out of 31 in the monthly 150 mg group, and 11 out of 34 in the placebo group. A secondary measure looked at changes in visual acuity (sharpness of vision, scored out of 100 letters) — the reported data shows average changes of +9 letters for the fortnightly 300 mg group, +16 letters for the 150 mg monthly group, and +5 letters for the placebo group; the figure for the 300 mg monthly group was not reported. A score measuring the use of other immune-suppressing medicines also showed changes, but data was only reported for two of the three AIN457 groups and the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have completed the full 24-week treatment period of the related core study.
Who may not be able to join:
- You are unwilling or unable to receive repeated injections under the skin.
- You are unable or unwilling to follow the study procedures and attend required follow-up appointments.
- You have a physical or mental health condition that, in the doctor's opinion, would prevent you from following the study rules or completing the study (confirm with trial site).
- There may be additional requirements not listed here that could affect your eligibility (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.